Jonathan Loree

This is an absolutely outstanding review on the management of patients with metastatic gastric cancer. I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam @YJanjigianMD @amalsargsyan and all the other co-authors I could not find on X... Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily. This should be a required read for all who take care of patients with gastric cancer. nature.com/articles/s4157…

@GillSharlene @CDNCancerTrials @JeanneTie Great to hear from @JeanneTie and look for new opportunities to work together with @GICancer. Also excited to plan the BATTMAN trials upcoming launch in Australia and New Zealand. Botensilimab plus balstilimab in #mcrc

#CCTG2026 @CDNCancerTrials 🇨🇦 A pleasure to host @JeanneTie to our CCTG Annual Meeting to advance our strong history of trials collaboration with @GICancer #formerlyAGITG 🇦🇺 🇳🇿 Special shout out to her #ILoveCanada earrings! ❤️

🌐 BATTMAN trial begins in MSS metastatic colorectal cancer On April 1, 2026, Agenus announced that the first patient has been enrolled in the phase III BATTMAN trial. BATTMAN is a global, randomized phase III study evaluating botensilimab + balstilimab vs best supportive care in patients with refractory, unresectable MSS metastatic colorectal cancer. The trial is being conducted across international sites and represents a potential registrational study in this setting. @Agenus_Bio @oncodaily @jonathanloree @garo_armen 📎oncodaily.com/oncolibrary/ba… #OncoDaily #GIOncology #ColorectalCancer #Immunotherapy #ClinicalTrials

Sharing the final publication and schema! @NANETS1 Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors doi.org/10.1530/ERC-25…

@OHSUKnight study showed standard dose (35mg/m2 bid) Trifluridine (Lonsurf) wk 1, 3 and 5 of #radiation for stage 2/3 #rectalcancer was safe with TNT. 56% of patients did Watch and Wait. ➡️New option for patients with 5-FU toxicity/contraindications❓ clinical-colorectal-cancer.com/article/S1533-…

Check out our new @NANETS Guidelines for Stage I-III Rectal NETs! Big updates in: - staging with MRI & PET Dotatate - advanced excision for < vs. >10 mm tumors - management of R1 excision - surgery - follow-up @AmanChauhanMD @OncoThor @FlavioRochaMD doi.org/10.1530/ERC-25…

Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use. sciencedirect.com/science/articl… #NETs #PRRT #NETTER2 #oncology

@aparna1024 Prognostic vs predictive important as well. Stellar looked pretty similar for HR and one of our biggest randomized data sets.

Less novel from when we first set out to do this, but we thought it was important to look at our own data not just in terms of ICI response but to put more numbers behind what the median OS is in a non-LM versus LM population to help with understanding of benefit.

@fireflyann @BCCancer @bccancerfdn @coloncanada Thanks for sharing both here and in the other groups!

@jonathanloree @BCCancer @bccancerfdn @coloncanada Ill circle back and post in fb groups I think FIT tests every 5 years from 30 to 45 makes financial sense. Fine with FIT at 45 if no family history. Definitely a colonoscopy at 50. But if non-compliance, keep the FITs coming

How would you prefer to be screened for colorectal cancer? 🩺 We’re surveying people to better understand preferences — including whether blood-based tests could reduce barriers. Please retweet & Share your voice: rc.bcchr.ca/redcap/surveys… @BCCancer @bccancerfdn @coloncanada

Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: buff.ly/pVU9ts3

AI meets digital pathology! 🔬 We used machine learning on whole-slide images of neuroendocrine tumors to classify grade, differentiation & prognosis. ✍ Authors: Amir Hadjifaradji et al. @jonathanloree @BCCancer @bccancerfdn 🌻 Read in @Cancers_MDPI mdpi.com/2072-6694/17/1…

A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" onlinelibrary.wiley.com/doi/10.1111/li…

@ronanhsieh @smitha42 Looking forward to working with you!

Receiving this confirmation letter on the last day of 2025 is so meaningful to me! I am so excited to join NCI Colon Task Force as an early career investigator under the leadership of @smitha42 @jonathanloree Look forward to the next 3 years of research discussion together. I feel humble and eager to learn more from many experts in the field. Special thanks to SWOG GI leadership for giving me this opportunity. @IbrahimSahinMD1

The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early nature.com/articles/s4158…

So Dill started this to help Canadian patients... and once he got the platform running for Canada... he made it global. In a weekend. Oh, Canada! @ccranorg @coloncanada @CAMO_ACOM @CDNCancerTrials @uoftmedicine @Sunnybrook @BCCancer @GillSharlene @jonathanloree @ocall0

@RonaYaeger Similar in CO.26 pubmed.ncbi.nlm.nih.gov/36007218/, however didn’t see responses: pubmed.ncbi.nlm.nih.gov/38727700/

We looked at this exact question and found that high TMB after targeted therapy, which is more striking in plasma than in tissue, is not sufficient to engender a response to immunotherapy. Manuscript just out! aacrjournals.org/clincancerres/…

Results from DYNAMIC-III RCT of ctDNA-guided adjuvant tx in stage III colon cancer in Nature Med. 🙏 to pts, providers & @JeanneTie 🇨🇦🇦🇺 @CDNCancerTrials & @GICancer Collab #ESMO2025 Presidential | Supported by @CIHR_IRSC & @cancersociety in 🇨🇦 🔗 rdcu.be/eLTj8

Excited to be at the #ESMO25 launch of the phase 3 @CDNCancerTrials 🇨🇦 #BATTMAN CO.33 BOT/BAL vs BSC in refractory MSS mCRC #unmetneed #trialsthatmatter Congrats to @jonathanloree 🙌 @ocall0 @Agenus_Bio @GICancer @JeanneTie Let’s get this done! 🇨🇦 🇦🇺 🇫🇷 @coloncanada @ccranorg @OncoAlert